Investigating Pathways for Intervention: Targeting RIPK1 in ALS

Time: 1:30 pm
day: Day Two


  • Assessing RIPK1 kinase activity modulates inflammatory signaling in microglia and astrocytes
  • RIPK1 is elevated in ALS patient spinal cords and RIPK1 kinase inhibition delays ALS disease progression in the SOD1G93A mouse model
  • Reviewing the Himalaya trial using a RIPK1 inhibitor to treat ALS patients